Zydus Secures USFDA Approval For Generic Medication

Zydus Lifesciences said that it has gained FDA permission to offer a generic medicine to treat postherpetic neuralgia. Zydus Lifesciences announced in a regulatory filing that the US Food and Drug Administration (USFDA) has granted final permission to manufacture and distribute Gabapentin tablets in 300 mg and 600 mg dosages, respectively.

The pharmaceutical company is the first to gain final approval for generic Gabapentin tablets (300 mg and 600 mg), according to the announcement. The drug company announced that the medicine will be available immediately in the United States.

As per IQVIA data, the product had an annual sales of USD 85 million in the US. Shares of Zydus were trading 2.27 per cent down at Rs 735.30 apiece on the BSE, as per economic times.

Zydus Lifesciences Limited is an Indian multinational pharmaceutical business located in Ahmedabad. It mostly manufactures generic pharmaceuticals. In 2020, the company rated 100th on the Fortune India 500 list.

Zydus Cadila develops and manufactures a wide range of pharmaceuticals, diagnostics, herbal items, skincare products, and other over-the-counter products from twenty-five manufacturing facilities throughout India. The company began producing generics for hepatitis C treatment in late 2015, following the conclusion of a voluntary license deal with Gilead.